Celldex Therapeutics (CLDX) Interest & Investment Income (2012 - 2026)
Celldex Therapeutics' (CLDX) quarterly Interest & Investment Income came in at -$1.1 million in Q1 2026, down 534.65% year-on-year from $254000.0 in Q1 2025, and up 95.09% quarter-over-quarter from -$22.5 million in Q4 2025.
Celldex Therapeutics (CLDX) Interest & Investment Income (2012 - 2026) Analysis & Trends
Celldex Therapeutics' Interest & Investment Income history runs 15 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- On a quarterly basis, Interest & Investment Income fell 534.65% year-over-year to -$1.1 million in Q1 2026; TTM through Mar 2026 was -$17.2 million, a 144.69% decrease from a year earlier, with the FY2025 full-year figure at $312000.0, down 99.16% from the prior year.
- Interest & Investment Income rose to -$1.1 million in Q1 2026 per CLDX's latest filing, from -$22.5 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $35.2 million in Q4 2024 and bottomed at -$22.5 million in Q4 2025.
- The 5-year median for Interest & Investment Income is $63000.0 (2023), against an average of $1.5 million.
- Across the five-year window, Interest & Investment Income sank 89000.0% in 2022 and soared 5468.25% in 2024, its largest moves.
- Year by year, Interest & Investment Income stood at $1.4 million in 2022, then soared by 214.94% to $4.3 million in 2023, then surged by 715.44% to $35.2 million in 2024, then plunged by 163.75% to -$22.5 million in 2025, then jumped by 95.09% to -$1.1 million in 2026.
- Per Business Quant, the three latest CLDX Interest & Investment Income figures stand at -$1.1 million (Q1 2026), -$22.5 million (Q4 2025), and $6.6 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Celldex Therapeutics | 2.34 Bn | 2.34 Bn | -1.44 Mn | -1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.10 Mn |
| Dec 31, 2025 | -22.46 Mn |
| Sep 30, 2025 | 6.57 Mn |
| Jun 30, 2025 | -229,000.00 |
| Mar 31, 2025 | 254,000.00 |
| Dec 31, 2024 | 35.24 Mn |
| Sep 30, 2024 | 3.51 Mn |
| Jun 30, 2024 | -464,000.00 |
| Mar 31, 2024 | -1.06 Mn |
| Dec 31, 2023 | 4.32 Mn |
| Sep 30, 2023 | 63,000.00 |
| Jun 30, 2023 | -51,000.00 |
| Mar 31, 2023 | 863,000.00 |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 305,000.00 |
| Jun 30, 2022 | -529,000.00 |
| Mar 31, 2022 | -1.78 Mn |
| Dec 31, 2021 | -654,000.00 |
| Sep 30, 2021 | 145,000.00 |
| Jun 30, 2021 | 5,000.00 |